The most impressive finding was that the GPC-1+ crExos distinguished patients with PDAC and pancreatic cancer precursor lesions (PCPL) from healthy donors and BPD patients; the sensitivity and specificity of GPC-1+ crExos prediction are 100% compared with CA19-9 (the clinical standard tumor biomarker for patients with PDAC). Here, GPC1 is linked to neoplasm.